Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
63 hedge funds and large institutions have $10.7M invested in Navidea Biopharmaceuticals Inc. in 2016 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 14 increasing their positions, 19 reducing their positions, and 27 closing their positions.
15% less funds holding
Funds holding: 74 → 63 (-11)
26% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 19
33% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 27
69% less call options, than puts
Call options by funds: $13K | Put options by funds: $42K
77% less capital invested
Capital invested by funds: $46.7M → $10.7M (-$36M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.34M |
| 2 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
+$707K |
| 3 |
Goldman Sachs
New York
|
+$662K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$549K |
| 5 |
LCM
Laurion Capital Management
New York
|
+$431K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$3.35M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$2.03M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.97M |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$1.31M |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$1.23M |
NAVB Hedge Fund Activity: Q2 2016 in Review
63 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q2 2016, worth a combined $10.7M — down 77% from $46.7M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of NAVB and 18 opened new positions — a net loss of 9 holders — while 19 trimmed existing stakes and 14 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $1.34M. The largest seller was BlackRock Fund Advisors, cutting an estimated $3.35M.
- 63 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q2 2016, down from 74 in Q1 2016.
- Funds reported $10.7M of Navidea Biopharmaceuticals Inc. stock for Q2 2016, down 77% quarter-over-quarter.
- 18 funds opened new Navidea Biopharmaceuticals Inc. positions in Q2 2016 and 27 closed out, a net change of -9 holders.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q2 2016 was Millennium Management, an estimated $1.34M added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q2 2016 was BlackRock Fund Advisors, an estimated $3.35M sold.
Based on aggregated 13F filings for Q2 2016.